This document summarizes the content on this page and details how our portfolio can help you detect, reduce the risk of, and respond to AF, and also treat paroxysmal AF in your patients.
Reveal LINQ™ ICM
The world's smallest, most accurate ICM5
Up to 3-year longevity for long-term monitoring
Visia AF MRI™ VR ICD
The only single chamber ICD that detects AF using the TruAF™ Detection Algorithm and a traditional lead
Managed Ventricular Pacing (MVP) reduces unnecessary RV pacing by 99%.13
Reactive ATP™ Algorithm reduces the duration of AT/AF15:
46% reduction in AF risk16
A safe and effective alternative after anti-arrhythmic drugs (AAD) for the treatment of paroxysmal AF (PAF), the first-generation Arctic Front™ Cryoballoon demonstrated 69.9% freedom from AF at 12 months compared to 7.3% with AAD.2
Arctic Front Advance™ Cryoballoon
75.3% freedom from AF at 24 months18
Relative to radiofrequency, cryoballoon demonstrated:*
The cryoballoon is indicated for the treatment of drug refractory paroxysmal AF
In a large randomized, controlled trial comparing cryoballoon to radiofrequency catheter ablation, the cryoballoon met the primary safety and efficacy endpoints of non-inferiority and did so with shorter and more consistent procedure times.20 While a predefined secondary analysis demonstrated significantly fewer reinterventions and rehospitalizations favoring cryoballoon.19
Pürerfellner H, et al. Adapting detection sensitivity based on evidence of irregular sinus
arrhythmia. Europace. Published online October 3, 2017.
Packer DL, et al. Cryoballoon ablation of pulmonary veins for paroxysmal atrial fibrillation: first results of the North American Arctic Front (STOP AF) pivotal trial. J Am Coll Cardiol. 2013;61(14): 1713-23.
Boriani G, et al. Heart Rhythm. 2015;12:1192-1200.
Chun KRJ, et al. J Am Heart Assoc. 2017 Jul 27;6(8).
ICM Competitive Comparison Guide. Medtronic data on file. 2017.
Nölker G, et al. J Cardiovasc Electrophysiol. 2016;27: 1403-1410.
Sanna T, et al. New Engl J Med. 2014;370:2478-2486.
Reiffel JA, et al. JAMA Cardiol. 2017;2:1120-1127.
Purerfellner H, et al. Accuracy of Atrial Tachyarrhythmia Detection in Implantable Devices with Arrhythmia Therapies. Pacing Clin Electrophysiol. July 2004;27:983-992.
Ziegler PD, et al. Accuracy of Atrial Fibrillation Detection in Implantable Pacemakers. Presented at HRS 2013 (PO02-08).
Medtronic Data on File. QADoc DSN026170, Version 2.0, “AT/AF Duration Performance Comparison.”
Boriani G, et al. Understanding the incidence of AF in single-chamber ICD patients: a real-world analysis. Presented at Europace 2017.
Gillis AM, Pürerfellner H, Israel CW, et al. Reduction of unnecessary right ventricular pacing due to the managed ventricular pacing (MVP) mode in patients with symptomatic bradycardia. Benefit for both sinus node disease and AV block indications. Presented at HRS 2005 (Abstract AB21-1).
Sweeney MO, et al. Circulation. 2003;107:2932-2937.
Hudnall, Harrison. Reactive Atrial-based Antitachycardia Pacing Therapy to Slow Progression of Atrial Fibrillation. August 2017, Medtronic Data on File.
Birnie D, et l. Heart Rhythm. 2017;14:1820-1825.
Plummer CJ, et al. Heart Rhythm. 2018;15:369-375.
Knight B, et al. Second Generation Cryoballoon Ablation in Paroxysmal Atrial Fibrillation Patients: 24 Month Safety and Efficacy from the STOP-AF Post Approval Study. Presented at HRS 2017 (Abstract).
Kuck KH, et al. Cryoballoon or radiofrequency ablation for symptomatic paroxysmal atrial fibrillation: reintervention, rehospitalization, and quality-of-life outcomes in the FIRE AND ICE trial. Eur Heart J. 2016; Oct 7;37:2858-2865.
Kuck KH, et al. Cryoballoon or Radiofrequency Ablation for Paroxysmal Atrial Fibrillation. N Engl J Med. 2016; 374(23): 2235-45.